RT Journal Article
T1 Identification of a Shared Microbiomic and Metabolomic Profile in Systemic Autoimmune Diseases.
A1 Bellocchi, Chiara
A1 Fernández-Ochoa, Álvaro
A1 Montanelli, Gaia
A1 Vigone, Barbara
A1 Santaniello, Alessandro
A1 Quirantes-Piné, Rosa
A1 Borrás-Linares, Isabel
A1 Gerosa, Maria
A1 Artusi, Carolina
A1 Gualtierotti, Roberta
A1 Segura-Carrettero, Antonio
A1 Alarcón-Riquelme, Marta E
A1 Beretta, Lorenzo
K1 Sjögren’s syndrome
K1 metabolomics
K1 microbiomic
K1 primary anti-phosholipid syndrome
K1 systemic autoimmune diseases
K1 systemic lupus erythematosus
K1 undifferentiated connective tissue diseases
AB Dysbiosis has been described in systemic autoimmune diseases (SADs), including systemic lupus erythematosus (SLE), Sjögren's syndrome (SjS), and primary anti-phosholipid syndrome (PAPS), however the biological implications of these associations are often elusive. Stool and plasma samples from 114 subjects, including in SLE (n = 27), SjS (n = 23), PAPs (n = 11) and undifferentiated connective tissue (UCTD, n = 26) patients, and geographically-matched healthy controls (HCs, n = 27), were collected for microbiome (16s rRNA gene sequencing) and metabolome (high-performance liquid chromatography coupled to mass spectrometry) analysis to identify shared characteristics across diseases. Out of 130 identified microbial genera, a subset of 29 bacteria was able to differentiate study groups (area under receiver operating characteristics (AUROC) = 0.730 ± 0.025). A fair classification was obtained with a subset of 41 metabolic peaks out of 254 (AUROC = 0.748 ± 0.021). In both models, HCs were well separated from SADs, while UCTD largely overlapped with the other diseases. In all of the SADs pro-tolerogenic bacteria were reduced, while pathobiont genera were increased. Metabolic alterations included two clusters comprised of: (a) members of the acylcarnitine family, positively correlating with a Prevotella-enriched cluster and negatively correlating with a butyrate-producing bacteria-enriched cluster; and (b) phospholipids, negatively correlating with butyrate-producing bacteria. These findings demonstrate a strong interaction between intestinal microbiota and metabolic function in patients with SADs.
SN 2077-0383
YR 2019
FD 2019-08-23
LK http://hdl.handle.net/10668/14445
UL http://hdl.handle.net/10668/14445
LA en
DS RISalud
RD Apr 18, 2025